<div id="readability-page-1"><div> <p>By Josh Beckerman</p> <pre></pre> <p>   Novavax shares declined right after The Wall Street Journal reported that the Food and Drug Administration is unlikely to give full approval soon for a company Covid-19 vaccine, but then the stock recovered. </p> <p>   Shares went as low as $5.70. They recently traded at $6.20, up 3.2%. </p> <p>   The vaccine is approved for emergency use. The FDA had set an April 1 deadline for a decision on whether to grant a normal, full approval, the WSJ reported. </p> <pre></pre> <p>   Write to josh.beckerman@wsj.com </p> <pre></pre> <p>   (END) Dow Jones Newswires</p> <p>   April 02, 2025 13:06 ET (17:06 GMT)</p><p>Copyright (c) 2025 Dow Jones &amp; Company, Inc.</p></div></div>

诺瓦瓦克斯医药

<p>诺瓦瓦克斯医药的股票在《华尔街日报》报道 FDA 不太可能很快授予其 Covid-19 疫苗完全批准后，最初下跌。股价跌至 5.70 美元，但随后回升至 6.20 美元，反映出 3.2% 的涨幅。该疫苗目前拥有紧急使用授权，FDA 的决定截止日期定于 4 月 1 日</p>

诺瓦瓦克斯在《华尔街日报》关于其疫苗 FDA 状态的报道后股价下跌，但随后恢复